The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma
Abstract
Purpose: To evaluate the effect of disease sites and prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131 I-MIBG) treatment of patients with resistant neuroblastoma. Patients and Methods: One hundred sixty-four patients with progressive, refractory or relapsed high-risk neuroblastoma, age 2 to 30 years, were treated in a limited institution phase II study. Patients with cryopreserved hematopoietic stem cells (n = 148) were treated with 18 mCi/kg of 131 I-MIBG. Those without hematopoietic stem cells (n = 16) received 12 mCi/kg. Patients were stratified according to prior myeloablative therapy and whether they had measurable soft tissue involvement or only bone and/or bone marrow disease. Results: Hematologic toxicity was common, with 33% of patients receiving autologous hematopoietic stem cell support. Nonhematologic grade 3 or 4 toxicity was rare, with 5% of patients experiencing hepatic, 3.6% pulmonary, 10.9% infectious toxicity, and 9.7% with febrile neutropenia. The overall complete plus partial response rate was 36%. The response rate was significantly higher for patients with disease limited either to bone and bone marrow, or to soft tissue (compared with patients with both) for patients with fewer than three prior treatment regimens and for patients older than 12 years. The event-free survival (EFS) and overall survival (OS) times were significantly longer for patients achieving response, for those older than 12 years and with fewer than three prior treatment regimens. The OS was 49% at 1 year and 29% at 2 years; EFS was 18% at 1 year. Conclusion: The high response rate and low nonhematologic toxicity with 131 I-MIBG suggest incorporation of this agent into initial multimodal therapy of neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Self-citationMatthay, K. K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., Weinberg, V. K., & Price, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222
Self-citationLe Deley, M.-C., Leblanc, T., Shamsaldin, A., Raquin, M.-A., Lacour, B., Sommelet, D., Chompret, A., Cayuela, J.-M., Bayle, C., Bernheim, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.100 · Cited by 216
Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 197
Self-citationNeuroblastoma in adults and adolescents: An indolent course with poor survival
Franks, L. M., Bollen, A., Seeger, R. C., Stram, D. O., & Matthay, K. K. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970515)79:10<2028::aid-cncr26>3.0.co;2-v · Cited by 163
Self-citationLashford, L. S., Lewis, I. J., Fielding, S. L., Flower, M. A., Meller, S., Kemshead, J. T., & Ackery, D. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1889 · Cited by 163
Matthay, K. K., Panina, C., Huberty, J. P., Price, D. C., Glidden, D. V., Tang, H. R., Hawkins, R. A., Veatch, J., & Hasegawa, B. H. (2001) · PubMed · Cited by 161
Self-citationSeeger, R. C., Reynolds, C. P., Gallego, R., Stram, D. O., Gerbing, R. B., & Matthay, K. K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4067 · Cited by 159
Self-citationGaze, M. N., Chang, Y.-C., Flux, G., Mairs, R. J., Saran, F. H., & Meller, S. T. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.195 · Cited by 141
Yanik, G. A., Levine, J. E., Matthay, K. K., Sisson, J. C., Shulkin, B. L., Shapiro, B., Hubers, D., Spalding, S., Braun, T., Ferrara, J. L. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.124 · Cited by 137
Self-citationDuBois, S. G., Messina, J. A., Maris, J. M., Huberty, J. P., Glidden, D. V., Veatch, J., Charron, M., Hawkins, R. A., & Matthay, K. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.058 · Cited by 117
Self-citationGaraventa, A., Bellagamba, O., Piccolo, M. S. L., Milanaccio, C., Lanino, E., Bertolazzi, L., Villavecchia, G., Cabria, M., Scopinaro, G., Claudiani, F., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6694223 · Cited by 106
Klingebiel, T., Bader, P., Bares, R., Beck, J., Hero, B., Jürgens, H., Lang, P., NIETHAMMER, D., Rath, B., & Handgretinger, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00130-0 · Cited by 103
Weiss, B., Vora, A., Huberty, J. P., Hawkins, R. A., & Matthay, K. K. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200307000-00009 · Cited by 85
Self-citationMessina, J. A., Cheng, S., Franc, B. L., Charron, M., Shulkin, B. L., To, B., Maris, J. M., Yanik, G. A., Hawkins, R. A., & Matthay, K. K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20777 · Cited by 84
Self-citationMastrangelo, S., Tornesello, A., Diociaiuti, L., Pession, A., Prete, A., Rufini, V., Troncone, L., & Mastrangelo, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1645 · Cited by 80
Second Tumors After Treatment of Childhood Malignancies
Robison, L. L., & Mertens, A. C. (1993) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30248-x · Cited by 79
131I-MIBG as a first-line treatment in high-risk neuroblastoma patients
Hoefnagel, C. A., deKraker, J., OLMOS, R. A. V., & te, P. A. V. (1994) · Nuclear Medicine Communications · doi:10.1097/00006231-199409000-00008 · Cited by 66
Lumbroso, J., Hartmann, O., & Schlumberger, M. J. (1992) · PubMed · Cited by 41
Voûte, P. A., Hoefnagel, C. A., de Kraker, J., Olmos, R. A. V., Bakker, D. J., & van der Kleij, A. J. (1991) · PubMed · Cited by 39
Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.
Hutchinson, R. J., Sisson, J. C., Miser, J., Zasadny, K. R., Normolle, D. P., Shulkin, B. L., Francis, I. R., Wieland, D. M., & Shapiro, B. (1991) · PubMed · Cited by 34
Cited by
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Self-citationMatthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationAdvancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Self-citationOverview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Metadata
- Authors
- Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., Hawkins, R. A., & Maris, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-03-20
- Volume
- 25
- Issue
- 9
- Pages
- 1054-1060
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127775057
- Cited by
- 264
- References
- 26
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.